Titilola Temitope Sode

Titilola Sode practices at Peachtree Dermatology Associates in Atlanta, Georgia.

Titilola Sode's NPI, 1003203381, was assigned on April 23, 2015. Titilola Sode graduated from Georgetown University School of Medicine in 2015. Titilola Sode holds Texas license S5781.

Titilola Sode's primary practice is Peachtree Dermatology Associates, at 371 E Paces Ferry NE Rd, Atlanta, GA 30305 in Fulton County. The practice phone is (404) 355-1919.

Titilola Sode's primary practice is Peachtree Dermatology Associates in Atlanta, Georgia. The medical group on file is Epiphany Dermatology. Dmand AI also links Titilola Sode to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Titilola Sode practices, 2 sites in all. Vendor and product names are available with a free account.

Dermatopathology is Titilola Sode's primary specialty in the NPI Registry, under taxonomy code 207ND0900X. Titilola Sode is board certified in dermatology by the American Board of Dermatology. Titilola Sode is licensed in Texas.

CMS data shows 2,240 Medicare services from Titilola Sode across 14 procedure codes in 2024, for 1,434 Medicare patients. Medicare paid $65,165 for them. Every service was in an office.

CMS counts 1,434 Medicare patients who saw Titilola Sode in 2024. The largest group is 65 to 74, with 636 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 3% are also on Medicaid. Their average risk score is 1.04, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Titilola Sode's median patient age at 66, with 58% women.

In 2024, Titilola Sode wrote 357 Medicare Part D claims for 149 patients. 96% of them were for generic drugs. CMS names the drug for 250 of them, across 11 drugs with 11 or more claims each, at $5,140 in total drug cost. In 2023, CMS named 282 claims across 14 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Titilola Sode for performance year 2024, reported as part of a group. Titilola Sode accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 111 procedures of removal of skin lesions by Titilola Sode, more than 76% of the clinicians it reports for that procedure.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

CMS Open Payments shows 427 general payments to Titilola Sode from 28 drug and device companies from 2020 to 2025. Food and beverage make up the largest share, 97% of the total. Abbvie Inc. paid the most, $2,615.

Titilola Sode graduated from Georgetown University School of Medicine in 2015.